Skip to main content
GDTC
NASDAQ Life Sciences

Chairman Buys $106K in Shares, Plans Further Purchases Amidst Financial Distress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.95
Mkt Cap
$10.415M
52W Low
$0.68
52W High
$3.68
52W Position info
40% above low
Off High info
74% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

GDTC sits 40% above its 52-week low of $0.68 on light trading volume (0.2× avg).

Summary

CytoMed Therapeutics' Chairman and Director purchased over $106,000 worth of shares in a private transaction and intends to buy more, signaling strong insider confidence amidst the company's financial distress.


Key Events · Ownership and Investor Activity · GDTC

  • Chairman's Share Purchase

    Mr. Choo Chee Kong, Chairman and Director, acquired 112,000 ordinary shares in a privately negotiated transaction on May 13, 2026.

  • Significant Insider Investment

    The purchase represents approximately $106,000, a substantial investment for a company with a market capitalization of around $10 million.

  • Intent for Further Accumulation

    Mr. Choo stated his intention to negotiate privately with other shareholders to further increase his stake in the company.

  • Context of Financial Distress

    This insider buying occurs after the company recently disclosed a going concern warning and widened net losses, making the vote of confidence particularly notable.


Analysis · GDTC · Life Sciences

The Chairman and Director, Choo Chee Kong, personally acquired a significant block of shares, representing over 1% of the company's market capitalization. This transaction, coupled with his stated intent to increase his holdings further, signals strong insider confidence at a time when the company has disclosed a going concern warning and widened losses. It suggests a belief in the company's future despite its current financial challenges.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GDTC was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $0.68 to $3.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GDTC - Latest Insights

GDTC
Oct 13, 2026, 6:14 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.8114
Real-time Price: $0.773 info
Change: -$0.0384 (-5%) info
Market Cap: $9.147M info
GDTC
Oct 09, 2026, 7:43 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.8114
Real-time Price: $0.773 info
Change: -$0.0384 (-5%) info
Market Cap: $9.147M info
GDTC
Sep 30, 2026, 9:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.9197
Real-time Price: $0.773 info
Change: -$0.1467 (-16%) info
Market Cap: $9.147M info
GDTC
Jul 24, 2026, 12:33 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $0.990
Real-time Price: $0.773 info
Change: -$0.217 (-22%) info
Market Cap: $9.147M info
GDTC
Jun 23, 2026, 12:14 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.996
Real-time Price: $0.773 info
Change: -$0.223 (-22%) info
Market Cap: $9.147M info